Blavatnik Fund for Innovation at Yale

The Blavatnik Fund for Innovation at Yale sits inside Yale Ventures and serves Yale's life-sciences commercialization work. It is an internal program for Yale faculty-led translational research, backed by the Blavatnik Family Foundation and positioned as one of Yale's core venture-building tools. Yale describes the fund as a $65 million initiative. Awards run from about $30,000 to $300,000, with a median actual award of $150,000, and the cycle is annual. The program is restricted to Yale faculty investigators and Yale spinouts with less than $500,000 in prior dilutive funding, and it concentrates on life sciences, therapeutics, and diagnostics. Yale Ventures reports roughly $6 million in annual translational funding across its programs, which frames the Blavatnik Fund as one part of a larger internal support system. The fund is strongest for translational projects that can move from academic discovery toward commercial development, especially when a team can show a plausible development path and a clear clinical or technical need. Yale's own outcome figures point to venture formation, venture fundraising, regulatory progress, and clinical trial starts. In practice, this is a faculty-only route for serious life-sciences translation, not a broad external grant call.

No upcoming rounds verified. Cadence: Annual.